Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field212
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol57
Genetic load in incomplete lupus erythematosus46
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease43
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children42
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus42
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases41
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort39
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus37
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms36
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE35
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine32
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus31
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial28
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus28
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus27
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials26
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance24
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit24
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response23
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory23
Canadian workplace experiences of systemic lupus erythematosus (SLE)21
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort21
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus20
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards20
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort20
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus19
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated19
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA19
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression19
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts19
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice19
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE18
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden18
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort18
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort17
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE16
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis16
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study16
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler16
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond15
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus15
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway15
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE14
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study14
Canadian patient experiences of lupus nephritis: a qualitative analysis14
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus14
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus14
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE13
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA13
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis13
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE13
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes13
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development13
Discrepant anti-dsDNA testing between EliA andCrithidiain ANA negative samples: just a false positive?13
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas13
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a13
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups13
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus13
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study12
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption12
Lupus spectrum ambiguity has long-term negative implications for patients12
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease12
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up12
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis12
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C312
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study12
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density11
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms11
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history11
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study11
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE11
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus10
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies10
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus10
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-13210
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study10
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus10
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis10
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry10
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease10
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)10
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica9
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?9
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial9
Investigations intoSCAMP5,a candidate lupus risk gene expressed in plasmacytoid dendritic cells9
Validation of eight endotypes of lupus based on whole-blood RNA profiles9
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus8
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms8
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort8
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data8
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus8
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort8
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus8
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen8
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE8
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study8
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations8
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database8
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study8
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus8
0.053319931030273